Relmada Therapeutics, Inc. Common Stock (RLMD) Stock Price
RLMDStock
$4.59+630.46%52W
Market Cap$489.61M
P/E—
PEG Ratio—
Div yield—
Beta0.50
RLMD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)1.01%
Price vs S&P 500 (4W)-15.48%
VGM Score51.04
RLMD Earnings Surprise History
Q3 25-0.30est. —
Q4 25-0.29est. -0.14
Q2 26-0.11est. -0.20
RLMD Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.27
4.25
4.25
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RLMDRelmada Therapeutics, Inc. Common Stock | — | — | C | $4.59 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Relmada Therapeutics, Inc. Common Stock
Relmada Therapeutics is a clinical-stage biotech company developing esmethadone (REL-1017), an oral NMDA receptor antagonist for depression and other central nervous system disorders. The company is focused on addressing high unmet medical needs in CNS disease treatment through novel drug formulations.